ArticleActa Cardiologica Sinica2026
Bortezomib Suppresses Abnormal Proliferation, Migration, and Phenotypic Switching of Aortic Smooth Muscle Cells.
Article in Acta Cardiologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherosclerosis is the leading cause of cardiovascular disease and mortality worldwide. The proliferation, migration, and phenotypic switching of vascular smooth muscle cells are central to its pathogenesis. Bortezomib, the first Food and Drug Administration-approved proteasome inhibitor for multiple myeloma, suppresses the proliferation and migration of pulmonary artery smooth muscle cells. However, its effects on aortic vascular smooth muscle cells (AoSMCs) remain unclear. Methods: Rat AoSMCs were treated with platelet-derived growth factor-BB (PDGF-BB) or angiotensin II (Ang II), with or without bortezomib. Cytotoxicity, proliferation, and migration were assessed by MTT, wound healing, and Boyden chamber assays. Intracellular and mitochondrial ROS were measured by DCFH-DA and MitoSOX. mRNA and protein levels of bone morphogenetic protein-2 (BMP-2), Runt-related transcription factor 2 (Runx2), α-smooth muscle actin (α-SMA), phosphorylated extracellular signal-regulated kinase (ERK), and phosphorylated protein kinase B (Akt) were assessed by RT-qPCR and Western blotting. Calcium deposition was assessed using Alizarin Red S staining. Results: Bortezomib attenuated PDGF-BB and Ang II-induced proliferation and migration of AoSMCs accompanied by reduced ROS production and decreased phosphorylation of ERK and Akt. Furthermore, bortezomib suppressed PDGF-BB- and Ang II-induced osteogenic markers (BMP-2 and Runx2) and calcium deposition, while restoring the contractile marker α-SMA, which was inhibited by PDGF-BB and Ang II. Conclusions: Bortezomib attenuated PDGF-BB- and Ang II-induced proliferation, migration, and phenotypic switching of AoSMCs, potentially through reduced ROS production. Mechanistically, bortezomib inhibited ERK and Akt phosphorylation and restored a contractile phenotype. These findings suggest that proteasome inhibition may offer a novel therapeutic approach to modulate vascular remodeling in atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.